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ORIGINAL ARTICLE

Chemotherapy and Survival for Patients With Multiple
Myeloma
Findings From a Large Nationwide and Population-Based Cohort
Nidhi Rohatgi, MD, MS,* Xianglin L. Du, MD, PhD,* Ann L. Coker, PhD,*
Lemuel A. Moye, MD, PhD,† Michael Wang, MD,‡ and Shenying Fang, MD, MS*

Objective: To assess the patterns of chemotherapy use for patients
with multiple myeloma and to determine if chemotherapy is effective in prolonging survival outside the clinical trial settings.
Methods: We studied a nationwide and population-based retrospective cohort of 4902 patients ⱖ65 years of age with stage II or III
multiple myeloma from 1992 to 1999, identified from the Surveillance, Epidemiology, and End-Results-Medicare data. Multivariate
logistic regression was used to estimate the odds ratio of receiving
chemotherapy and Cox proportional hazard model was used to
estimate the hazard ratio of mortality associated with chemotherapy.
Results: Of 4902 patients with stage II or III multiple myeloma,
52.0% received chemotherapy during the course of the disease. The
receipt of chemotherapy decreased significantly with age from
65.7% in the 65- to 69-year age group to 34.3% in those ⱖ80 years.
Blacks (47.6%) were less likely to receive chemotherapy than whites
(52.8%). Use of chemotherapy decreased significantly with comorbidity scores and increased over time. Risk of all-cause mortality
was significantly reduced in patients who received chemotherapy
compared with those who did not (adjusted hazard ratio ⫽ 0.65;
95% confidence interval ⫽ 0.61– 0.69). A similar pattern as observed for myeloma-specific mortality (0.61; 0.56 – 0.67). Survival
benefit increased with increasing cycles of chemotherapy (P ⬍ 0.001
for trend) and was significant across different age groups, gender,
ethnic groups, and comorbidity scores.
Conclusion: Chemotherapy was significantly associated with increased survival in patients with multiple myeloma outside the
clinical trial settings. This survival benefit was significant across
different groups by age, gender, race, and comorbidity. A substantial number of patients with multiple myeloma did not receive chemotherapy.

From the Divisions of *Epidemiology and †Biostatistics, School of Public
Health, University of Texas Health Science Center, Houston, TX; and
‡Department of Lymphoma and Myeloma, University of Texas M. D.
Anderson Cancer Center, Houston, TX.
Reprints: Xianglin L. Du, MD, PhD, Division of Epidemiology, University of
Texas School of Public Health, 1200 Herman Pressler Drive, RAS-E631,
Houston, TX 77030. E-mail: Xianglin.L.Du@uth.tmc.edu.
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M

ultiple myeloma, a cancer of the plasma cell, is the
second most prevalent hematologic cancer in the
United States, after non-Hodgkin’s lymphoma.1,2 The American Cancer Society estimated that there will be 16,570 new
cases of multiple myeloma in the United States in 2006 and
about 11,310 patients are estimated to die of multiple myeloma, accounting for 2% of all cancer deaths.1,2 This disease
primarily affects the elderly population as the median age of
incidence was 70 years and the median age of death was 74
years.1,2 While the incidence is higher in blacks than whites
and other ethnic populations,1–3 the etiology of this disease is
largely unknown.4 –16
Standard therapy for elderly patients with multiple
myeloma has been melphalan plus prednisone (MP) for
several decades.17–23 For patients younger than 65 years,
high-dose chemotherapy and induction therapy followed by
autologous stem-cell transplantation is recommended as the
first line therapy.24 –29 More recent studies found that combination chemotherapy regimens with melphalan may prove
superior.30 –33 Although chemotherapy has been well documented to be efficacious in prolonging survival in clinical
trials, little is known about how chemotherapy is practiced
among patients living in the community and whether this
therapy is also effective outside the clinical trial settings.
Elderly patients have been disproportionately under-represented in the clinical trials, yet this population accounts for
most cancer cases.34 –37 Therefore, we undertook a large
nationwide and population-based study in elderly patients
diagnosed with multiple myeloma in 11 areas of the
National Cancer Institute’s Surveillance, Epidemiology,
and End Results (SEER) tumor registries to determine
what proportion of patients received chemotherapy as
recommended, what factors were associated with not receiving
this therapy, and whether chemotherapy was effective in prolonging survival among elderly patients outside the clinical trial
settings.
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PATIENTS AND METHODS
Data Sources
We used the SEER-Medicare linked data for cases
diagnosed with multiple myeloma in 1992–1999. The SEER
program, supported by the National Cancer Institute, includes
population-based tumor registries in 11 selected geographic
areas1,38,39: the metropolitan areas of San Francisco/Oakland,
Detroit, Atlanta and Seattle; Los Angeles county; the San
Jose-Monterey area; and the states of Connecticut, Iowa, New
Mexico, Utah, and Hawaii, covering over 14% of the U.S.
population. The registries ascertain all newly diagnosed multiple myeloma cases from multiple reporting sources, such as
hospitals, outpatient clinics, laboratories, private medical
practitioners, nursing/convalescent homes/hospices, autopsy
reports, and death certificates.
The Medicare program provides payments for hospital,
physician, and outpatient medical services for more than 97%
of persons 65 years of age or older.38,39 Medicare claims data
are available through 2002. For persons aged 65 years or
older appearing in the SEER records, Medicare eligibility
could be identified for 94% of these cases. The method of
linking these data has been described elsewhere.38,39 The
Committee for the Protection of Human Subjects at the
University of Texas Health Science Center at Houston approved this study.

Study Population
Our study was based on the analytical SEER-Medicare
files that excluded patients who did not have full coverage of
both Medicare Part A and Part B to ensure the completeness
of their Medicare claims, and those who were members of
health maintenance organizations because Medicare claims of
these patients may be incomplete. We studied 4902 patients
with late stage (Durie-Salmon stage II or III) multiple myeloma because these patients represented over 90% of all
cases with multiple myeloma and chemotherapy was universally recommended for these patients.17–27 In this database,
there were also 146 patients with early-stage (Durie-Salmon
stage I) multiple myeloma who were generally asymptomatic
and were often recommended for a period of active observation instead of chemotherapy,26 whose treatment recommendations are not homogeneous. Therefore, these small numbers
of cases were excluded from further analyses.

Outcome Variables
Survival time in months was calculated from the date of
diagnosis to the date of death or to the date of last follow-up
(December 31, 2002). The cause of death is identified by the
SEER program through linking the SEER data with the
National Death Index data from the National Center for Vital
Statistics. All-cause mortality was defined as death from any
cause indicated in the SEER registry data. Patients still alive
at the last date of follow-up were censored in the time to
event survival analysis by the Kaplan-Meier method and Cox
proportional hazard regression model. Multiple myelomaspecific mortality was defined as multiple myeloma as the
underlying cause of death. In this cause-specific analysis,
© 2007 Lippincott Williams & Wilkins

patients who died of causes other than multiple myeloma
or who were still alive at the date of last follow-up were
censored.

Treatment of Multiple Myeloma
Chemotherapy
Detailed methods for the identification of chemotherapy use through Medicare claims have been previously described.40,41 In brief, patients with cancer were defined as
having received chemotherapy if any of the following Medicare procedure codes so indicated during the course of the
disease: the ICD-9-CM procedure code of 99.25 and V codes
of V58.1, V66.2, or V67.2; the common procedure codes
of 96400-96549, J8530-J8999, or J9000-J9999, or Q0083Q0085, and revenue center codes of 0331, 0332 and
0335.42– 45 The commonly used chemotherapy drug includes
melphalan (J9245 or J8600). Since melphalan (plus prednisone) is standard therapy and several combination chemotherapy regimens yielded similar survival benefit, we included these patients as having received chemotherapy and
did not specify specific drug therapy.

Radiation Therapy
Patients were defined as having received radiation therapy if either SEER or Medicare claims so indicated.46

Stem Cell Transplantation
Patients were defined as having received stem cell
transplantation if the following Medicare claims indicated so:
ICD-9-CM codes of 4100 – 4109, or CPT codes of 38230,
38231, 38240, and 38241.42– 45 Because only 41 (0.8%) cases
received it and it was not recommended in the elderly
patients, this variable was not included in the final analysis.

Socioeconomic Status
The percent of persons living below the poverty line
at the census tract level from the 1990 census available in
the SEER-Medicare linked data was used to define socioeconomic status. This variable was selected because for
elderly Medicare beneficiaries, the poverty level could be
the most directly relevant proxy measure of their economic
status.47 Two other socioeconomic variables (percent of
adults aged ⱖ25 who had less than 12 years of education
and median annual household income at the census tract
level) were also examined in the analysis in place of
poverty. Because these 2 socioeconomic measures yielded
the similar results, only the results using poverty were
reported.

Comorbidity Score
Comorbidity was ascertained from Medicare claims by
identifying 18 comorbid diagnoses between one year prior to
and one month after the diagnosis of multiple myeloma.
Details on creating a weighted comorbidity score have been
previously reported.48
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Other Characteristics
Patient and tumor characteristics such as age at diagnosis (categorized as 65– 69, 70 –74, 75–79, ⱖ80 years),
gender, race/ethnicity (white, black, and others), year of
diagnosis (1992–1999), and geographic area (11 SEER areas)
available from SEER were assessed as correlates of the
receipt of chemotherapy and survival.

Statistical Analysis
Differences in the distribution of baseline characteristics between patients who received chemotherapy and those
who did not were tested using the 2 statistic, odds ratios
(ORs), and associated 95% confidence intervals (CIs). The
3-year observed survival rate was the proportion of patients
who survived for at least 3 years in those diagnosed in 1992
to 1999, and the 5-year observed survival rate was the
proportion of patients who survived for at least 5 years in
those diagnosed in 1992 to 1997. Patients who were lost to
follow-up, withdrawn, or still alive at the last date of follow-up (December 31, 2002) were censored in the time to
event survival analysis using the Kaplan-Meier method and
Cox proportional hazard model.49 –51 In multiple myelomaspecific mortality analysis, patients who died of causes other
than multiple myeloma were additionally censored. The median survival time with 95% confidence interval was estimated from the Kaplan-Meier survival curve using the
LIFETEST procedure.49,50
Cox proportional hazard regression model was used for
survival analysis using the PHREG procedure available in the
SAS system.50 The proportionality assumption was considered to be satisfied when the log-log Kaplan-Meier curves for
survival functions by the receipt of chemotherapy were parallel and did not intersect.51 Multiple Cox regression analyses
were adjusted for age, gender, race/ethnicity, radiation therapy, comorbidity score, year of diagnosis, geographic area,
and socioeconomic status.

RESULTS
Table 1 presents the distribution of the 4902 elderly
patients with stage II or III multiple myeloma and the comparison between those who received chemotherapy and those
who did not, by age, gender, race/ethnicity, comorbidity,
radiation therapy, socioeconomic status, year of diagnosis,
and geographic area. Median age at diagnosis in these patients was 76 years, ranging from 65 to 104 years. Median age
was 78 years for those who did not receive chemotherapy
compared with 74 years for those who received chemotherapy. The distribution of patients who received chemotherapy
was different from those who did not in terms of age,
comorbidity, radiation therapy, year of diagnosis and geographic area, but there was no significant difference in terms
of gender, race/ethnicity, and socioeconomic status.
Table 2 presents the number and percentage of patients
receiving chemotherapy for all patients and stratified by other
factors, and also presents the adjusted odds ratios of receiving
chemotherapy. Overall, 52.0% of patients with stage II or III
multiple myeloma received chemotherapy during the course
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of the disease. The receipt of chemotherapy decreased substantially by age from 65.7% in patients 65 to 69 years of age
to 34.3% in those ⱖ80 years of age. After adjusting for
gender, ethnicity, comorbidity, radiation therapy, socioeconomic status, year of diagnosis, and geographic areas, patients 70 to 79 years of age were 41% less likely to receive
chemotherapy (OR ⫽ 0.59; 95% CI, 0.49 – 0.70) compared
with patients 65 to 69 years of age. There was no significant
difference in the use of chemotherapy between men and
women. Black patients were 23% less likely to receive
chemotherapy compared with whites. The receipt of chemotherapy decreased significantly with increased comorbidity
scores, and those with comorbidity scores of 3 or higher were
almost twice as likely to receive no chemotherapy. Patients
who received radiation therapy were also more likely to
receive chemotherapy. The rate of receiving chemotherapy
decreased slightly from high to low socioeconomic status,
and increased significantly over time from 1992 to 1999.
There were also some geographic variations in the 11 SEER
registries.
Among 4902 patients included in this cohort who were
followed up for at least 3 years and up to 11 years (median
follow-up, 7.1 years), the 3-year overall observed survival
rate was 56.0% (2747 of 4902), and the 3-year multiple
myeloma-specific observed survival rate was 73.7% (3614 of
4902). The 5-year overall and myeloma-specific observed
survival rates were 43.6% (1664 of 3814) and 60.8% (2318 of
3184), respectively, among those patients who were diagnosed in 1992 to 1997 and followed up for at least 5 years.
Based on the Kaplan-Meier survival curve, the median survival time was 5.9 years (95% CI, 5.6 – 6.2) for patients
receiving chemotherapy and 1.6 years (95% CI, 1.4 –1.8) for
those who did not receive chemotherapy.
Table 3 presents the number and percent of observed
death within 3 years of diagnosis and by the date of last
follow-up, and also presents the adjusted hazard ratio of
mortality in association with the receipt of chemotherapy as
well as the number of cycles of chemotherapy (measured by
the number of claims for chemotherapy). The crude death
rates within 3 years of diagnosis and by the last follow-up
were lower in those who received chemotherapy than those
who did not. After adjusting for other potential confounding
factors, patients who received chemotherapy were 35% less
likely to die of all-causes (hazard ratio ⫽ 0.65; 95% CI,
0.61– 0.69) and 41% less likely to die of multiple myeloma
(hazard ratio ⫽ 0.61; 95% CI, 0.56 – 0.67) than those who did
not receive chemotherapy. The risk of call-cause mortality
and myeloma-specific mortality decreased with increasing
number of chemotherapy cycles (P ⬍ 0.001 for trend). For
example, compared with patients who did not receive chemotherapy, those who received 1 to 5 cycles were 16% less
likely to die of all-causes, whereas those who received 25 to
35 cycles were 53% less likely to die, after adjusting for age,
gender, race, comorbidity, radiation therapy, socioeconomic
status, year of diagnosis, and geographic area.
Figure 1 presents the Cox proportional hazard ratios
(95% CI) of all-cause and multiple myeloma-specific mortal© 2007 Lippincott Williams & Wilkins
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TABLE 1. Comparison of Characteristics Between Patients With Multiple Myeloma Who Received Chemotherapy and Those
Who Did Not (1992–1999)
Column % of Patients, Stratified
by the Receipt of Chemotherapy
Characteristic
Age (yr) 关median (range)兴
Age (yr)
65–69
70–74
75–79
ⱖ80
Gender
Male
Female
Race/ethnicity
White
Black
Others
Comorbidity scores
0
1
2
ⱖ3
Radiation therapy
No
Yes
Socioeconomic status (SES)
1st quartile (high SES)
2nd quartile
3rd quartile
4th quartile (low SES)
Missing
Year of diagnosis
1992
1993
1994
1995
1996
1997
1998
1999
SEER registry areas
San Francisco, CA
Connecticut
Detroit, MI
Hawaii
Iowa
New Mexico
Seattle, WA
Utah
Atlanta, GA
San Jose-Monterey, CA
Los Angeles, CA
Total

No. of Patients

% of Patients

76 (65–104)

Did Not Receive
Chemotherapy

Received Chemotherapy

78 (65–104)

74 (65–95)

P for Difference
Between 2
Groups

1018
1161
1179
1544

20.8
23.7
24.1
31.5

14.8
18.2
23.9
43.1

26.3
28.7
24.2
20.8

⬍0.001

2355
2547

48.0
52.0

46.8
53.2

49.2
50.8

0.082

3893
676
333

79.4
13.8
6.8

78.1
15.0
6.9

80.6
12.6
6.7

0.100

2292
1117
707
786

46.8
22.8
14.4
16.0

40.9
24.0
15.1
19.9

52.1
21.6
13.8
12.5

⬍0.001

3579
1323

73.0
27.0

78.9
21.2

67.6
32.4

⬍0.001

1211
1213
1256
1132
90

24.7
24.8
25.6
23.1
1.8

23.4
23.9
26.7
24.4
1.6

25.9
25.5
24.6
21.9
2.0

0.103

689
609
632
598
656
630
547
541

14.1
12.4
12.9
12.2
13.4
12.9
11.2
11.0

16.0
13.3
13.8
11.4
12.9
12.4
10.2
10.1

12.3
11.7
12.1
12.9
13.9
13.3
12.0
11.9

⬍0.001

380
653
907
91
704
214
531
260
277
210
675
4902

7.8
13.3
18.5
1.9
14.4
4.4
10.8
5.3
5.7
4.3
13.8
100.0

8.1
15.3
18.7
2.0
14.8
4.2
9.7
5.4
4.9
4.3
12.6
100.0

7.4
11.5
18.3
1.7
14.0
4.6
11.9
5.2
6.3
4.2
14.8
100.0

⬍0.001

© 2007 Lippincott Williams & Wilkins
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TABLE 2.
Myeloma

Percentage and Odds Ratio of Receiving Chemotherapy in Patients With Multiple

Characteristic
All patients
Age (yr)
65–69
70–74
75–79
ⱖ80
Gender
Male
Female
Race/ethnicity
White
Black
Others
Comorbidity scores
0
1
2
ⱖ3
Radiation therapy
No
Yes
Socioeconomic status (SES)
1st quartile (high SES)
2nd quartile
3rd quartile
4th quartile (low SES)
Missing
Year of diagnosis
1992
1993
1994
1995
1996
1997
1998
1999
SEER registry areas
San Francisco, CA
Connecticut
Detroit, MI
Hawaii
Iowa
New Mexico
Seattle, WA
Utah
Atlanta, GA
San Jose–Monterey, CA
Los Angeles, CA

Adjusted Odds Ratio*
(95% Confidence Interval)
of Receiving
Chemotherapy

No. of Patients

No. of Patients
Receiving
Chemotherapy

% of Patients
Receiving
Chemotherapy

4902

2547

52.0

1018
1161
1179
1544

669
732
617
529

65.7
63.1
52.3
34.3

1.00
0.91 (0.76–1.09)
0.59 (0.49–0.70)
0.29 (0.24–0.34)

2355
2547

1254
1293

53.3
50.8

1.00
0.99 (0.88–1.12)

3893
676
333

2054
322
171

52.8
47.6
51.4

1.00
0.77 (0.63–0.95)
0.86 (0.67–1.12)

2292
1117
707
786

1328
551
351
317

57.9
49.3
49.7
40.3

1.00
0.80 (0.68–0.93)
0.81 (0.68–0.97)
0.54 (0.45–0.64)

3579
1323

1722
825

48.1
62.4

1.00
1.53 (1.34–1.76)

1211
1213
1256
1132
90

660
650
627
558
52

54.5
53.6
49.9
49.3
57.8

1.00
0.91 (0.77–1.09)
0.77 (0.64–0.92)
0.84 (0.69–1.02)
1.15 (0.72–1.84)

689
609
632
598
656
630
547
541

313
297
307
329
353
339
306
303

45.4
48.8
48.6
55.0
53.8
53.8
55.9
56.0

1.00
1.09 (0.86–1.37)
1.13 (0.90–1.42)
1.57 (1.24–1.98)
1.52 (1.21–1.90)
1.65 (1.31–2.08)
1.66 (1.31–2.11)
1.68 (1.32–2.13)

380
653
907
91
704
214
531
260
277
210
675

189
293
467
44
356
116
303
132
161
108
378

49.7
44.9
51.5
48.4
50.6
54.2
57.1
50.8
58.1
51.4
56.0

1.00
0.65 (0.49–0.85)
0.97 (0.75–1.26)
0.80 (0.48–1.32)
0.96 (0.73–1.26)
0.95 (0.66–1.37)
1.12 (0.84–1.48)
0.87 (0.62–1.21)
1.29 (0.92–1.80)
0.86 (0.60–1.23)
1.28 (0.98–1.67)

*Adjusted for variables listed in the table.
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TABLE 3. Effect of Chemotherapy and the Number of Cycles of Chemotherapy on Mortality in Patients With Multiple
Myeloma With up to 11 Years of Follow-up

Chemotherapy Status
All-cause mortality
All patients
No chemotherapy
Receipt of chemotherapy
Cycle (no. of claims) of chemotherapy received
0 (no chemotherapy)
1–5
6–15
16–25
25–35
⬎35
Myeloma-specific mortality
All patients
No chemotherapy
Receipt of chemotherapy
Cycle (no. of claims) of chemotherapy received
0 (no chemotherapy)
1–5
6–15
16–25
25–35
⬎35

No. of Patients
(n ⴝ 4902)

No. (%) of Observed
Deaths Within
3 Years

No. (%) of Observed
Death by Last
Follow-up

Hazard Ratio*
(95% CI) of
Mortality

P

2355
2547

1458 (61.9)
697 (27.4)

2189 (93.0)
2313 (90.8)

1.00 (reference)
0.65 (0.61–0.69)

—
⬍0.001

2355
1067
643
298
172
367

1458 (61.9)
498 (46.7)
136 (21.2)
32 (10.7)
14 (8.1)
17 (4.6)

2189 (93.0)
1010 (94.7)
571 (88.8)
264 (88.6)
147 (85.5)
321 (87.5)

1.00 (reference)
0.84 (0.77–0.90)
0.63 (0.57–0.69)
0.55 (0.48–0.62)
0.47 (0.40–0.56)
0.45 (0.40–0.51)

—
⬍0.001
⬍0.001
⬍0.001
⬍0.001
⬍0.001

2355
2547

861 (36.6)
427 (16.8)

1101 (46.8)
1019 (40.0)

1.00 (reference)
0.61 (0.56–0.67)

—
⬍0.001

2355
1067
643
298
172
367

861 (36.6)
310 (29.1)
84 (13.1)
16 (5.4)
7 (4.1)
10 (2.7)

1101 (46.8)
501 (47.0)
248 (38.6)
98 (32.9)
51 (29.7)
121 (33.0)

1.00 (reference)
0.83 (0.75–0.93)
0.58 (0.51–0.67)
0.44 (0.36–0.54)
0.38 (0.28–0.50)
0.34 (0.28–0.41)

—
⬍0.001
⬍0.001
⬍0.001
⬍0.001
⬍0.001

*Hazard ratio (95% confidence internal) was the time to event analysis by censoring those who were lost to the follow-up or still alive at the end of follow-up, and simultaneously
adjusting for age, gender, race, comorbidity, radiation therapy, socioeconomic status, year of diagnosis, and SEER areas.

FIGURE 1. Hazard ratio (95% confidence interval) of all-cause (A) and
myeloma-specific (B) mortality in
patients with stage II to III multiple
myeloma who received chemotherapy compared with those who did
not, stratified by age, gender, race,
radiotherapy, and comorbidity
score.
© 2007 Lippincott Williams & Wilkins
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ity in patients who received chemotherapy compared with
those who did not, stratified by selected demographic factors
and radiation therapy. This was to determine whether the
pattern of improved survival associated with chemotherapy
was held within strata of these factors. Survival benefit of
chemotherapy was statistically significant in all strata of age,
gender, race, comorbidity, and radiation therapy. For example, the hazard ratio of all-cause mortality was 0.63 (95% CI,
0.58 – 0.67) in white patients with chemotherapy compared
with those without, whereas corresponding hazard ratio was
0.72 (95% CI, 0.61– 0.86) for blacks. Similarly, chemotherapy was associated with 25% to 40% reduction in mortality,
regardless of comorbidity scores.

DISCUSSION
It is important to assess whether the clinical treatment
guidelines for the receipt of chemotherapy as the standard of
care for elderly patients with stage II or III multiple myeloma
were being followed in the community practices and whether
any lack of appropriate therapy was associated with decreased survival. We found that receiving chemotherapy was
associated with 35% survival advantage, and this survival
benefit was significant across different age groups, ethnic
groups, gender, and comorbidity scores. However, a large
proportion of the elderly patients with stage II or III multiple
myeloma did not receive chemotherapy and the receipt of
chemotherapy decreased substantially with age.
Age is a major factor in determining cancer therapies.52–57 Several studies demonstrated that older patients
with breast cancer and colon cancer were significantly less
likely to receive chemotherapy according to the clinical
guidelines.52,56,57 Nonreceipt of chemotherapy among elderly
patients has been attributed to the lack of healthcare access.58
However, in our study, all patients had access to Medicare so
that these patients can be entitled for inpatient and outpatient
medical services across the United States. There were some
inconsistent findings about whether elderly patients were as
likely to tolerate the chemotherapy-related toxicities as
younger patients.59 – 62 Currently, many patients who receive
chemotherapy often receive antiemetics,63 and more patients
receive hematopoietic growth factors to prevent more serious
toxicities such as neutropenia and anemia.62,63 Nevertheless,
our study was consistent with previous reports, showing that
older patients were less likely to receive chemotherapy. Since
chemotherapy was associated with increased survival rate in
all age groups of the elderly patients with multiple myeloma,
it is therefore concerning if age is still a barrier to the
recommended therapy.
The Institute of Medicine has demonstrated convincing
and substantial disparities in the quality of health care among
various race/ethnic groups in the United States.58 Low socioeconomic status and poor access to medical care are the main
contributors in not receiving the recommended therapies. In
our study, black patients (47.6%) were significantly less
likely to receive chemotherapy than whites (52.8%), even
after adjusting for patient demographics and radiation therapy. Although a larger proportion of blacks lived in the
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lowest quartile of socioeconomic status, ethnic difference in
the receipt of chemotherapy did not change after adjusting for
socioeconomic status. Healthcare providers may also be a
factor in the disparities of receiving the standard of care.64
However, outcomes in patients with multiple myeloma were
similar across the ethnic groups as found in this as well as in
other studies.65,66 This may be due to the fact that socioeconomic status was not significantly associated with survival in
this study and ethnic difference in receiving chemotherapy
was relatively small.
As we found in this study, chemotherapy was effective
in prolonging survival among the community dwelling elderly patients. Although numerous clinical trials have well
documented the efficacy of chemotherapy, no study has been
conducted to evaluate the effectiveness of chemotherapy in
elderly patients outside the clinical trial settings. To the best
of our knowledge, this study is the first to demonstrate that
the efficacy of chemotherapy documented in clinical trials
settings has been translated into the “real world” effectiveness. This has a number of clinical and public health implications. First, patients enrolled in the clinical trials were often
motivated volunteers and highly selected because only those
relatively healthy patients with minimal comorbidity can be
eligible for the trials. Therefore, these patients are often not
representative of all the patients outside the clinical settings.
Our study documented that chemotherapy is also beneficial
for patients in the community. Second, elderly patients,
particularly oldest old (ⱖ80 years), are often underrepresented in the clinical trials.34 –37 It is often uncertain if the
efficacy documented in younger patients can still be generalizable to older ones. Findings from a large cohort of elderly
patients in this study suggested that survival benefit was
evident even in those very old patients as well. Furthermore,
in tumors such as breast cancer, survival benefit decreased
with advanced age due to decreased tumor sensitivity, inadequate dosage for the elderly patients, or concern about lack
of abilities in tolerating toxicity. However, our study showed
that oldest old patients can still benefit significantly from
chemotherapy. Survival benefit was significant in those without comorbid conditions as well as in those with comorbid
diseases.
Several limitations need to be noted. First, the study
population only included patients 65 years of age or older
who are not health maintenance organization members and
who have both Medicare Part A and Part B coverage. Findings may not be generalizable to a younger population.
However, because multiple myeloma is essentially a disease
of the elderly, the study findings may be applied to a large
number of cases. Targeting this population would have great
importance for much-needed research in identifying health
problems and for improving quality of life. Second, we are
unable to determine the actual doses of chemotherapy given.
However, we provided an estimate on the number of cycles
for receiving chemotherapy that was associated with decreasing mortality. Those who received more cycles of chemotherapy appeared to have greater benefits in mortality reduction.
Furthermore, information on the receipt of chemotherapy was
© 2007 Lippincott Williams & Wilkins
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based on Medicare claims for diagnostic and procedure codes.
There might be a possibility of missing claims for chemotherapy
in Medicare data, although overcoding on chemotherapy may be
unlikely.41 Finally, socioeconomic status was based on the 1990
census tract level. Although poverty, education, and household
income at the census tract level provided similar findings, there
may be residual confounding when the individual level socioeconomic status was not adjusted for in the analysis.

CONCLUSION
Chemotherapy was significantly associated with increased survival in patients with multiple myeloma outside
the clinical trial settings. This survival benefit was significant
across different ages, gender, and comorbidity. However,
substantial number of patients with stage II or III multiple
myeloma (48%) did not receive chemotherapy. Additional
studies to confirm these findings in younger populations and
to incorporate the quality of life issues may be helpful.
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